GlassScriptPhysician profile
Yelitza Silva
NPI 1497244610
$1,759.19
in general payments reported to CMS, 2019-2025
29 companies · $853 in 2025
The $853 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $130 · 2022: $52.29 · 2023: $376 · 2024: $347 · 2025: $853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,576.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $174.91 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $170.42 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Xeris Pharmaceuticals, INC. | $127.92 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $120.55 | 2023-2025 | |
| Recordati_rare_diseases_inc. | $120.03 | 2024-2025 | Isturisa |
| Tandem Diabetes Care, INC. | $117.35 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $88.38 | 2023-2025 | Dexcom G6 Transmitter |
| Mannkind Corporation | $82.77 | 2024-2025 | |
| Janssen Biotech, INC. | $73.98 | 2021-2023 | Rybrevant, Erleada |
| Pfizer INC. | $71.37 | 2021-2025 | |
| Genzyme Corporation | $67.54 | 2023 | |
| Insulet Corporation | $62.80 | 2023-2025 | Omnipod |
| Corcept Therapeutics | $62.79 | 2025 | Korlym |
| Amgen INC. | $50.49 | 2023-2025 | Prolia, Evenity, Tepezza |
| Sequel Med Tech, LLC | $40.86 | 2025 | Twiist |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $33.33 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.39 | 2025 | |
| Neurocrine Biosciences, INC. | $32.19 | 2025 | |
| Avanos Medical | $30.87 | 2022 | |
| Tersera Therapeutics LLC | $26.85 | 2023 | Zoladex |
| Ibsa Pharma INC. | $24.34 | 2025 | Flector, Licart, Tirosint |
| Abbott Laboratories | $23.75 | 2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $21.50 | 2025 | Farxiga |
| Halozyme INC | $20.73 | 2023 | |
| Beta Bionics, INC. | $19.88 | 2024 | Ilet Bionic Pancreas |
| Merck Sharp & Dohme LLC | $18.66 | 2023 | Keytruda |
| Ascensia Diabetes Care US INC. | $15.18 | 2024 | |
| Incyte Corporation | $14.08 | 2021 | |
| Puma Biotechnology, INC. | $13.28 | 2023 | Nerlynx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yelitza Silva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.